Fecal dipeptidyl peptidase-4 may be used as a noninvasive biomarker in patients with inflammatory bowel disease, according to research published in Clinical and Translational Gastroenterology.

“Although the diagnosis of IBD is still a challenge, over the past few years, several studies managed to identify key molecules involved in IBD pathogenesis. In this context, dipeptidyl peptidase-4 (DPP-4) emerged as a potential noninvasive biomarker of IBD activity and as a monitoring tool of the response to biological treatments,” Pedro Pinto-Lopes, MD, MSc, Centro Hospitalar Universitário

Full Article: https://www.healio.com/news/gastroenterology/20210415/fecal-dpp4-serves-as-a-biomarker-for-ulcerative-colitis-crohns-disease